These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17936806)

  • 1. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.
    Carter HB; Kettermann A; Warlick C; Metter EJ; Landis P; Walsh PC; Epstein JI
    J Urol; 2007 Dec; 178(6):2359-64; discussion 2364-5. PubMed ID: 17936806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
    Carter HB; Walsh PC; Landis P; Epstein JI
    J Urol; 2002 Mar; 167(3):1231-4. PubMed ID: 11832703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
    Berglund RK; Masterson TA; Vora KC; Eggener SE; Eastham JA; Guillonneau BD
    J Urol; 2008 Nov; 180(5):1964-7; discussion 1967-8. PubMed ID: 18801515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
    Khan MA; Carter HB; Epstein JI; Miller MC; Landis P; Walsh PW; Partin AW; Veltri RW
    J Urol; 2003 Dec; 170(6 Pt 1):2274-8. PubMed ID: 14634395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
    Aizer AA; Chen MH; Hattangadi J; D'Amico AV
    BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
    Ercole B; Marietti SR; Fine J; Albertsen PC
    J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.
    Makarov DV; Isharwal S; Sokoll LJ; Landis P; Marlow C; Epstein JI; Partin AW; Carter HB; Veltri RW
    Clin Cancer Res; 2009 Dec; 15(23):7316-21. PubMed ID: 19934305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.
    Moreira DM; Fleshner NE; Freedland SJ
    J Urol; 2015 Nov; 194(5):1258-63. PubMed ID: 25988518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study.
    Khatami A; Damber JE; Lodding P; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(3):213-7. PubMed ID: 12775279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
    Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
    J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
    BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.